@JenSeligmann
Pinned post
www.theguardian.com New drug could slow tumour regrowth in inoperable bowel cancer Adavosertib found to delay tumour growth in some patients in clinical trial, with few side effects Very proud and happy to share that our work on neoadjuvant IO in pMMR colon cancers has been published online in @Nature after presentation @myESMO #ESMO25. Preview: rdcu.be/eLTN1 Read on how genomic instability, P53mt and proliferation may aid in predicting responses.View quoted post on X
NICHE-2 absolutely delivers. Game over for chemo in dMMR colon cancer 💥🧬
In locally advanced dMMR colon cancer, FOxTROT already showed us chemo doesn’t work, and now NICHE-2 makes it undeniable.
💊 Neoadjuvant nivolumab + ipilimumab →
• 99% pathologic response
• 67% pathologic CR
• Zero recurrences to date at 3 years
🪦 This is the final coffin nail for perioperative chemotherapy in this setting. ATOMIC is already on life support despite being published less than a year ago.
The real question now: with Cercek’s rectal data, can we safely omit surgery next?
At minimum, this should be the new standard.
At maximum, it’s the start of a paradigm shift.
@OncoAlert @TheGutOncLab #ESMO25View quoted post on X
www.annalsofoncology.org Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon... The FOxTROT trial has reported advantages of neoadjuvant chemotherapy (NAC) in locally advanced colon cancer (LACC). In this article, we present results of the embedded randomised phase II trial... 
